Steigerwald Gordon & Koch Inc. Increases Position in Johnson & Johnson (NYSE:JNJ)

Steigerwald Gordon & Koch Inc. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,051 shares of the company’s stock after purchasing an additional 1,268 shares during the period. Johnson & Johnson accounts for about 3.0% of Steigerwald Gordon & Koch Inc.’s investment portfolio, making the stock its 9th largest holding. Steigerwald Gordon & Koch Inc.’s holdings in Johnson & Johnson were worth $12,514,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in JNJ. Lake Point Wealth Management raised its holdings in Johnson & Johnson by 144.4% during the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after purchasing an additional 169 shares in the last quarter. Islay Capital Management LLC bought a new stake in Johnson & Johnson during the second quarter worth approximately $42,000. FAI Wealth Management increased its holdings in shares of Johnson & Johnson by 45.9% in the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after buying an additional 101 shares in the last quarter. SeaBridge Investment Advisors LLC increased its holdings in shares of Johnson & Johnson by 160.0% in the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after buying an additional 200 shares in the last quarter. Finally, HWG Holdings LP bought a new position in shares of Johnson & Johnson in the second quarter valued at $49,000. 67.44% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have issued reports on JNJ. SVB Leerink reaffirmed an “outperform” rating on shares of Johnson & Johnson in a report on Wednesday, July 15th. Credit Suisse Group upped their price target on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday. Citigroup upped their price target on Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a report on Friday, July 17th. Raymond James upped their price target on Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Finally, Independent Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the company from $161.00 to $164.00 in a report on Monday, July 20th. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Buy” and an average target price of $164.93.

Johnson & Johnson stock opened at $148.10 on Friday. The company’s fifty day simple moving average is $148.57 and its 200-day simple moving average is $146.59. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.40. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The stock has a market cap of $389.92 billion, a P/E ratio of 23.29, a P/E/G ratio of 3.36 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, beating the consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The business had revenue of $21.08 billion for the quarter, compared to analysts’ expectations of $20.15 billion. During the same period in the previous year, the company posted $2.12 EPS. Johnson & Johnson’s revenue was up 1.7% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 8 earnings per share for the current fiscal year.

In related news, EVP Ashley Mcevoy sold 29,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the transaction, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at approximately $3,197,444.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the transaction, the executive vice president now directly owns 66,658 shares in the company, valued at $10,233,336.16. The disclosure for this sale can be found here. Corporate insiders own 0.27% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: The benefits and drawbacks of dollar cost averaging

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.